Bicara Therapeutics

An exciting moment for our team today as we celebrated becoming a public company by ringing the #OpeningBell at Nasdaq! This moment marks an important new chapter in our journey, reinforcing our commitment to developing therapies that could make a meaningful difference in the lives of those living with #cancer. We extend our gratitude to our hard working, dedicated and talented team whose drive and passion made this achievement possible. 🎉 #IPO

Bicara Chief Executive Officer Claire Mazumdar will present at the Stifel 2024 Healthcare Conference in New York, NY. View the details and access the live webcasts and replays on our website here: https://lnkd.in/gfy8e4NR

This morning, we announced our third quarter 2024 financial results and business update, highlighting the strong development progress we have made with ficerafusp alfa and the successful completion of our upsized initial public offering. For more details, read the full press release here: https://lnkd.in/gkPiFksa

🔬 Cancer doesn’t wait. Neither does Bicara Therapeutics. 👩⚕️ $BCAX’s mission as a clinical stage biotherapeutic company is clear: to turn groundbreaking discoveries into real, life-altering new cancer therapies. 🎉 Honored to be your exchange partner, congrats on becoming #NasdaqListed!

🔬 Cancer doesn’t wait. Neither does Bicara Therapeutics. 👩⚕️ $BCAX’s mission as a clinical stage biotherapeutic company is clear: to turn groundbreaking discoveries into real, life-altering new cancer therapies. 🎉 Honored to be your exchange partner, congrats on becoming #NasdaqListed!

We are excited to share that we have closed our IPO and are listed on Nasdaq as BCAX! This marks an important new chapter for our company as we aim to deliver transformative bifunctional therapies to patients with solid tumors. Thank you to all of our dedicated team members and partners for the continued support in helping us achieve this milestone. https://lnkd.in/eNGgtmQx

We are delighted to announce the appointment of Mike Powell and Chris Bowden to our board of directors. Both individuals are esteemed leaders in the biopharma industry, and their extensive expertise will be instrumental as we progress ficerafusp alfa (BCA101) into its late-stage development for recurrent/metastatic head and neck squamous cell carcinoma, as well as other indications. For further details, visit: https://lnkd.in/gDmvcMPR

On July 27, we honor World Head and Neck Cancer Day to raise awareness and highlight the importance of knowing about these #cancers, along with effective care and control. Head and Neck Cancer is associated with a number of risk factors, many of which can be avoided and early detection is key to successful treatment. Be aware of the signs and symptoms, and if in doubt, get checked out! #WHNCD2024

Today, we are at the 3rd Hawaii Summit on Thoracic Malignancies, and excited to share updated interim data from our ongoing, open-label Phase 1/1b dose expansion study of ficerafusp alfa (BCA101) in 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. #HNSCC is one of the most common cancers globally with a rising incidence, and this approach may become a new chemotherapy-free standard of care treatment for patients in need. Learn more in the release here: https://lnkd.in/e4PMdm6C

The two subtypes of Head and Neck Cancer (HNC) are distinctly associated with smoking/drinking and/or human papillomavirus (HPV) infection, and are often preventable. If diagnosed early, chances for survival can more than double. Screenings typically take less than 10 minutes. Get screened for HPV and HNC this #HeadandNeckCancerAwarenessMonth!